Shares of oncology-focused biotechnology company Sonnet BioTherapeutics (SONN) have plummeted more than 70% in price year-to-date due to its poor financials and the broad-based market sell-off. However, the company is…
Shares of oncology-focused biotechnology company Sonnet BioTherapeutics (SONN) have plummeted more than 70% in price year-to-date due to its poor financials and the broad-based market sell-off. However, the company is…